For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
FOXO4-DRI (also called Proxofim) is a 26-amino-acid cell-penetrating D-retro-inverso peptide designed to disrupt the FOXO4-p53 protein-protein interaction that keeps senescent cells alive. Published in Cell in 2017 by Baar et al. at Erasmus University Medical Center, it represents the first peptide-based senolytic: a compound that selectively induces apoptosis in senescent cells while sparing healthy tissue. In mouse studies, it reversed chemotoxicity from doxorubicin, restored fur density and fitness in fast-aging and naturally aged mice, and improved renal function. The mechanism has been structurally characterized by NMR in a 2025 Nature Communications paper. No human clinical trial has been published. Cleara Biotech, formed to commercialize the original work, has moved beyond FOXO4-DRI itself to develop optimized derivatives CL04177 and CL04183 now in pre-IND/IMPD studies. Widespread human self-experimentation with commercially available FOXO4-DRI is occurring without safety or efficacy data.
The complete FOXO4-DRI profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use